BioSpace News Archive

Transgene, a biotech company that designs and develops virus-based immunotherapeutics against cancer, announces that AstraZeneca has exercised its first license option for an Invir.IO™ oncolytic virus developed from their on-going OV collaboration.

RELIEF THERAPEUTICS Holding SA, a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, reported that the parent company of its collaboration partner, NRx Pharmaceuticals, Inc., has announced a new safety update on aviptadil, which is being tested in the ACTIV-3b Critical Care Phase 3 study sponsored by the U.S. National Institutes of Health.

Ultimovacs ASA, a clinical stage leader in immune stimulatory vaccines for cancer, announced that the first patient has been enrolled in the DOVACC study, a randomized Phase II clinical trial assessing the impact of the Company’s telomerase vaccine, UV1, on the standard of maintenance care in ovarian cancer.

BenevolentAI, a leading clinical-stage AI drug discovery company, announced that AstraZeneca has added a novel target for idiopathic pulmonary fibrosis, discovered using BenevolentAI’s platform, to its drug development portfolio.

VarmX announced treatment of the first subjects in its first-in-human study for lead compound VMX-C001, and the transition of VarmX from a preclinical into a clinical company.

Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors, announced that it has extended its patent estate with four key US and EU patents granted as part of the company’s foundational “Steyaert patents”.

The ZEISS Group ended fiscal year 2020/21 (end of reporting period: 30 September 2021 ) on an excellent note: its revenue rose by 20% to 7.529 billion euros (previous year: 6.297 billion euros ).

Mythic Therapeutics today announced its launch to develop smarter and safer antibody-drug conjugates (ADCs) with an oversubscribed Series B financing round of $103 million.

NTC Srl, R&D driven pharmaceutical company with headquarters in Italy, and I-MED Pharma Inc., a Canadian company specializing in dry eye diagnosis and management, announced that I-DEFENSE®, a long-lasting, lubricating ointment containing 0.4% sodium hyaluronate indicated for the relief of dry eyes and lagophthalmos symptoms has been successfully registered with the U.S.A. Food and Drug Administration.

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Swedish Orphan Biovitrum AB announced today that the European Commission (EC) has approved Aspaveli® (pegcetacoplan), the first and only targeted C3 therapy, for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH) who are anemic after treatment with a C5 inhibitor for at least three months.